Stockscreener 앱 받기
0.7328
1.81%
0.0146
전일 마감가:
$0.7182
열려 있는:
$0.7202
하루 거래량:
561.29K
Relative Volume:
0.06
시가총액:
$197.60M
수익:
$2.02M
순이익/손실:
$-97.59M
주가수익비율:
-1.2751
EPS:
-0.5747
순현금흐름:
$-102.38M
1주 성능:
+6.08%
1개월 성능:
+5.41%
6개월 성능:
-30.36%
1년 성능:
-70.52%
1일 변동 폭
$0.72
$0.74
1주일 범위
$0.6802
$0.74
52주 변동 폭
$0.5469
$2.55
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.7329 | 181.76M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
526.45 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.82 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
880.75 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.36 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.21 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Barclays | Overweight |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Humacyte Says US FDA Accepted IND for Human Trial of Coronary Tissue Engineered Vessel in Surgery - Moomoo
Humacyte Inc (HUMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
FDA accepts Humacyte IND for coronary bypass graft study - Investing.com
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting - The Manila Times
Humacyte Plans First Human Study of Bioengineered Vessel in Heart Bypass - Stock Titan
Humacyte Inc (HUMA) Cash Flow - TradingKey
Humacyte Inc (HUMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Humacyte Inc (HUMA) Institutional Confidence - TradingKey
HUMA|Humacyte Inc|Price:0.674|Chg%:+0.050 - TradingKey
Humacyte Inc (HUMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Humacyte Market Sentiment - Benzinga España
HUMA|Humacyte Inc|Price:0.625|Chg%:-0.014 - TradingKey
Price to sales forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Humacyte, Inc. (HUMA) Stock Analysis: Exploring a Potential 221% Upside in Biotech Innovation - DirectorsTalk Interviews
Humacyte Inc (HUMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Lobbying Update: $50,000 of HUMACYTE lobbying was just disclosed - Quiver Quantitative
Humacyte, Inc. (HUMA) suffers a larger drop than the general market: Key insights - MSN
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Enterprise value to EBIT forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Investor Notice: Robbins LLP Informs Stockholders of the Class A - GuruFocus
Humacyte, Inc. (HUMA) beats stock market upswing: What investors need to know - MSN
Humacyte appoints two nephrologists as commercial advisors By Investing.com - Investing.com South Africa
Humacyte appoints two nephrologists as commercial advisors - Investing.com
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access - The Manila Times
Two Kidney Specialists Join Humacyte Ahead of Planned Dialysis Access - Stock Titan
Form 13D/A HUMACYTE For: 13 July By Investing.com - Investing.com Nigeria
Fresenius to sell 5M Humacyte (HUMA) shares under Rule 10b5-1 plan - Stock Titan
Humacyte Inc (HUMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors - MSN
HUMAHumacyte Inc Options - Finviz
HUMA Should I Buy - Intellectia AI
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securitie - GuruFocus
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Enterprise value to revenue forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte Financial Disclosures & SEC Filings - TradingView
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Humacyte Announces $50 Million Public Offering of Common Stock - Global Legal Chronicle
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses - MSN
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market - MSN
Enterprise value to revenue forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Humacyte, Inc. (HUMA) latest stock news and headlines - Yahoo Finance Singapore
Price to book forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Price to sales forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Enterprise value to revenue forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Humacyte, Inc. Actuals & Estimates (NASDAQ:HUMA) - TradingView
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Humacyte Inc 주식 (HUMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Constantino Michael T. | Director |
May 18 '26 |
Buy |
0.89 |
11,000 |
9,840 |
43,950 |
| Sander Dale A. | CFO and Chief Corp. Dev. Off |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
267,213 |
| Parikh Shamik J | Chief Medical Officer |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
272,713 |
0.92%
0.19%
자본화:
|
볼륨(24시간):